Advertisement
U.S. markets open in 6 hours 6 minutes

Seelos Therapeutics, Inc. (SEEL)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.1990+0.0095 (+5.01%)
At close: 04:00PM EDT
0.2005 +0.00 (+0.75%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1895
Open0.1895
Bid0.0000 x 0
Ask0.2000 x 100
Day's Range0.1826 - 0.2034
52 Week Range0.1800 - 242.4000
Volume385,078
Avg. Volume2,005,188
Market Cap1.388M
Beta (5Y Monthly)1.86
PE Ratio (TTM)0.01
EPS (TTM)21.9400
Earnings DateNov 12, 2024 - Nov 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press Finance

    Seelos: Q2 Earnings Snapshot

    NEW YORK (AP) — Seelos Therapeutics, Inc. SEEL) on Wednesday reported earnings of $1.7 million in its second quarter. The New York-based company said it had profit of 12 cents per share.

  • InvestorPlace

    3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

    Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn’t a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy). Likewise, Congressman Da

  • PR Newswire

    Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share